Pfiz­er ex­pects few­er peo­ple need­ed for Ly­me dis­ease vac­cine tri­al

Pfiz­er said it ex­pects few­er peo­ple will be need­ed to com­plete its Phase III tri­al of Val­ne­va’s Ly­me dis­ease vac­cine can­di­date than orig­i­nal­ly thought. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER